- Home
- CBRL vs ATTO Comparison
CBRL vs ATTO Comparison
Compare CBRL & ATTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CBRL | ATTO |
|---|---|---|
| Founded | 1969 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 1998 | 2026 |
Fundamental Metrics
Financial Performance| Metric | CBRL | ATTO |
|---|---|---|
| Price | $58.77 | $14.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $50.71 | $42.20 |
| AVG Volume (30 Days) | ★ 1.1M | 420.4K |
| Earning Date | 09-23-2026 | 09-02-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $3,030,445,000.00 | N/A |
| Revenue This Year | $1.72 | N/A |
| Revenue Next Year | $2.28 | N/A |
| P/E Ratio | $41.07 | ★ N/A |
| Revenue Growth | ★ 3.56 | N/A |
| 52 Week Low | $24.85 | $15.48 |
| 52 Week High | $60.26 | $28.00 |
Technical Indicators
Market Signals| Indicator | CBRL | ATTO |
|---|---|---|
| Relative Strength Index (RSI) | 65.52 | 30.31 |
| Support Level | $28.37 | N/A |
| Resistance Level | $59.96 | $18.38 |
| Average True Range (ATR) | 2.56 | 1.33 |
| MACD | 0.96 | -0.33 |
| Stochastic Oscillator | 98.80 | 2.89 |
Price Performance
Historical ComparisonAbout CBRL Cracker Barrel Old Country Store Inc
Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants menu that features home-style country food and a wide variety of decorative and functional items such as rocking chairs, holiday and seasonal gifts, toys, apparel, cookware and foods.
About ATTO Attovia Therapeutics Inc. Common Stock
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.